Gullone v. Bayer Corp.

408 F. Supp. 2d 569, 2006 U.S. Dist. LEXIS 313
CourtDistrict Court, N.D. Illinois
DecidedJanuary 5, 2006
DocketNo. MDL 986; Nos. 93 C 7452, 1:03 CV 8928
StatusPublished
Cited by1 cases

This text of 408 F. Supp. 2d 569 (Gullone v. Bayer Corp.) is published on Counsel Stack Legal Research, covering District Court, N.D. Illinois primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Gullone v. Bayer Corp., 408 F. Supp. 2d 569, 2006 U.S. Dist. LEXIS 313 (N.D. Ill. 2006).

Opinion

MEMORANDUM OPINION

GRADY, District Judge.

The basic issue presently before the court in this multidistrict litigation is whether we should grant the defendants’ motion to dismiss one of the constituent cases pursuant to the doctrine of forum non conveniens. The plaintiffs in the case of Gullone v. Bayer Corp., transferred here from the Northern District of California for pretrial proceedings, are six citizens and residents of Italy, one citizen and resident of Germany, and eight citizens and residents of the United Kingdom (“U.K.”). All of the plaintiffs in the MDL are persons who allege that they contracted either the HIV virus or the Hepatitis B virus by exposure, either directly or indirectly, to blood-clotting products manufactured by the four defendants for use by persons suffering from hemophilia. The plaintiffs are either hemophiliacs who allegedly used the products or spouses who allege infection as a result of the spousal relationship. The defendants are Bayer [571]*571Corporation, an Indiana corporation, Baxter Healthcare Corporation, a Delaware corporation, Armour Pharmaceutical Company, Inc., a Delaware corporation, and Alpha Therapeutic Corporation, a California corporation. Jurisdiction is based upon diversity of citizenship.

The Judicial Panel on Multidistrict Litigation has transferred a number of cases, including Gullone, to this district for pretrial proceedings. In addition, several similar cases have been filed in this district and are being treated as part of the multidistrict litigation.

The cases now pending are actually the “second generation” of this consolidated litigation and have been so labeled by the MDL Panel. The “first generation” cases were resolved some years ago, most of them by way of a class settlement of approximately 6000 claims.1

A discussion of the first generation claims is necessary to an analysis of the present forum non conveniens motion. For convenience, we will quote from one of our opinions regarding those earlier cases:

Plaintiffs in these consolidated cases are persons suffering from hemophilia, a hereditary disease in which the protein that causes blood clotting is missing. The principal treatment for the disease is the intravenous injection of the missing protein, derived from the plasma of blood donors. Four of the defendants are pharmaceutical companies which collect and process the plasma to derive “factor concentrates,” which are then sold for use by hemophiliacs. The manufacturing process for deriving the finished factor concentrate from blood plasma is known as “fractionating,” and the four defendants involved in the present dispute are known as “fractionators.”
In the early 1980s, some hemophiliacs using the defendants’ factor concentrates began to show symptoms of a disease later identified as Acquired Immune Deficiency Syndrome (“AIDS”). As is now known, this disease is transmitted by the Human Immunodeficiency Virus (“HIV”). Plaintiffs allege that they were infected with the virus as a result of injecting the defendants’ factor concentrates derived from donors who were themselves infected. Plaintiffs allege a variety of negligent acts and omissions on the part of the fractionator defendants, principally the failure to sterilize their products to eliminate the possibility of viral infection (viral inactivation), failure to screen plasma donors so as to eliminate classes of persons, such as intravenous drug users, who presented a high risk of viral infectivity, failure to engage in “surrogate testing” of donors to determine whether they had viral infections (such as hepatitis) suggesting the possibility of other, undetectable viruses as well, failure to warn users of their products of the danger of infection once they knew or reasonably should have known that the newly observed symptoms were caused by a disease that was viral and blood-borne, and failure to withdraw their products from the market when the danger of infection became known.
Defendants have a variety of defenses to plaintiffs’ negligence allegations. [572]*572Among the more important are that the virus in question was unknown and unforeseeable during any period of time defendants were not taking the precautions plaintiffs claim they should have been taking and that, as soon as the presence of a new virus became apparent, they did all they reasonably could have done to eliminate it from their products. With regard to each of the measures plaintiffs allege should have been undertaken earlier, defendants respond with specific reasons as to why it was not feasible to do so. For instance, heat treatment of the concentrates, the method of viral inactivation plaintiffs claim should have been used, was not, in defendants” view, a procedure that was technologically effective or even legally permissible for them to use until most of the plaintiffs had already been infected with the virus. Defendants contend that they began the effective heat treatment of their products as soon as they were able to do so.
A number of lawsuits based upon diversity of citizenship were filed against the fractionators in various federal districts by infected hemophiliacs, their spouses, guardians, and personal representatives. On December 7, 1993, the Judicial Panel on Multidistrict Litigation transferred the then pending federal cases to this court for consolidated pretrial proceedings pursuant to 28 U.S.C. § 1407. The total number of cases now pending, including tag-a-longs, is approximately 192. Another 300 similar cases are pending in various state courts. A Steering Committee appointed by the court, chosen from among the attorneys who represent plaintiffs in individual cases, has been conducting the litigation on behalf of all plaintiffs.
Prior to the MDL consolidation, thirteen cases were tried to verdict in state and federal courts. Twelve verdicts were for defendants and the lone plaintiffs’ victory was reversed on appeal. No cases have been tried subsequent to the MDL consolidation.
Not long after the MDL consolidation, plaintiffs moved for nationwide class certification in one of the cases, contending that the claims of the plaintiffs were typical of thousands'of claims which had accrued to infected hemophiliacs across the country. We declined to certify all issues for class treatment, but did decide that certification of the negligence issues was appropriate pursuant to Rule 23(c)(4)(A) of the Federal Rules of Civil Procedure. Wadleigh v. Rhone-Poulenc Rorer, Inc., 157 F.R.D. 410 (N.D.Ill.1994). We were of the view that trial of the class action would effectively decide the litigation one way or the other, and therefore directed the parties to concentrate on preparing for trial of the class action. This concentration was consistent with the purpose of the MDL, inasmuch as the common issues which would have been tried in Wadleigh were identical to the common issues that prompted the MDL consolidation. However, Wadleigh was not to be tried, at least as a class action.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

In Re Factor Viii or Ix Concentrate Blood Products
408 F. Supp. 2d 569 (N.D. Illinois, 2006)

Cite This Page — Counsel Stack

Bluebook (online)
408 F. Supp. 2d 569, 2006 U.S. Dist. LEXIS 313, Counsel Stack Legal Research, https://law.counselstack.com/opinion/gullone-v-bayer-corp-ilnd-2006.